Blueprint Medicines Quarterly Income Statements Chart
Quarterly
|
Annual
Blueprint Medicines Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | |||||||||||||||||||||||||||||||||||||||||
| product revenue | 149,413,000 | 144,125,000 | 128,184,000 | 114,115,000 | 92,525,000 | 71,034,000 | 54,228,000 | 39,876,000 | 39,069,000 | 30,064,000 | 28,634,000 | 28,454,000 | 23,841,000 | 20,029,000 | 17,270,000 | 11,433,000 | 8,955,000 | 6,688,000 | 6,308,000 | 5,680,000 | 3,458,000 | ||||||||||||||||||||
| collaboration, license and other revenue | 2,241,000 | 24,042,000 | |||||||||||||||||||||||||||||||||||||||
| total revenues | 149,413,000 | 146,366,000 | 128,184,000 | 138,157,000 | 96,116,000 | 71,957,000 | 56,566,000 | 57,570,000 | 63,287,000 | 38,781,000 | 65,977,000 | 36,547,000 | 62,731,000 | 107,021,000 | 24,188,000 | 27,295,000 | 21,576,000 | 34,106,000 | 745,118,000 | 8,343,000 | 6,167,000 | ||||||||||||||||||||
| yoy | 55.45% | 103.41% | 126.61% | 139.98% | 51.87% | 85.55% | -14.26% | 57.52% | 0.89% | -63.76% | 172.77% | 33.90% | 190.74% | 213.79% | -96.75% | 227.16% | 249.86% | ||||||||||||||||||||||||
| qoq | 2.08% | 14.18% | -7.22% | 43.74% | 33.57% | 27.21% | -1.74% | -9.03% | 63.19% | -41.22% | 80.53% | -41.74% | -41.38% | 342.45% | -11.38% | 26.51% | -36.74% | -95.42% | 8831.06% | 35.28% | |||||||||||||||||||||
| cost and operating expenses: | |||||||||||||||||||||||||||||||||||||||||
| cost of sales | 2,802,000 | 7,447,000 | 1,932,000 | 7,593,000 | 3,191,000 | 260,000 | 2,782,000 | 2,323,000 | 3,175,000 | 4,848,000 | 3,000,000 | 4,886,000 | 5,079,000 | 7,549,000 | 3,790,000 | 6,493,000 | 102,000 | 128,000 | 146,000 | 127,000 | 24,000 | ||||||||||||||||||||
| gross profit | 146,611,000 | 138,919,000 | 126,252,000 | 130,564,000 | 92,925,000 | 71,697,000 | 53,784,000 | 55,247,000 | 60,112,000 | 33,933,000 | 62,977,000 | 31,661,000 | 57,652,000 | 99,472,000 | 20,398,000 | 20,802,000 | 21,474,000 | 33,978,000 | 744,972,000 | 8,216,000 | 6,143,000 | ||||||||||||||||||||
| yoy | 57.77% | 93.76% | 134.74% | 136.33% | 54.59% | 111.29% | -14.60% | 74.50% | 4.27% | -65.89% | 208.74% | 52.20% | 168.47% | 192.75% | -97.26% | 153.19% | 249.57% | ||||||||||||||||||||||||
| qoq | 5.54% | 10.03% | -3.30% | 40.50% | 29.61% | 33.31% | -2.65% | -8.09% | 77.15% | -46.12% | 98.91% | -45.08% | -42.04% | 387.66% | -1.94% | -3.13% | -36.80% | -95.44% | 8967.33% | 33.75% | |||||||||||||||||||||
| gross margin % | 98.12% | 94.91% | 98.49% | 94.50% | 96.68% | 99.64% | 95.08% | 95.96% | 94.98% | 87.50% | 95.45% | 86.63% | 91.90% | 92.95% | 84.33% | 76.21% | 99.53% | 99.62% | 99.98% | 98.48% | 99.61% | ||||||||||||||||||||
| research and development | 91,890,000 | 83,672,000 | 85,300,000 | 84,270,000 | 88,191,000 | 97,536,000 | 110,252,000 | 110,063,000 | 112,073,000 | 117,840,000 | 127,981,000 | 128,466,000 | 103,133,000 | 356,876,000 | 84,419,000 | 80,027,000 | 79,710,000 | 77,404,000 | 74,230,000 | 91,079,000 | 84,146,000 | 88,646,000 | 81,453,000 | 87,101,000 | 74,250,000 | 70,532,000 | 64,562,000 | 58,573,000 | 49,954,000 | 43,629,000 | 39,300,000 | 33,271,000 | 28,487,000 | 24,073,000 | 18,150,000 | 21,273,000 | 17,635,000 | 16,431,000 | 11,681,000 | 11,243,000 | 9,232,000 |
| selling, general and administrative | 95,807,000 | 96,450,000 | 89,926,000 | 89,339,000 | 83,557,000 | 79,315,000 | 70,741,000 | 71,931,000 | 70,950,000 | 64,020,000 | 57,608,000 | 58,688,000 | 57,058,000 | 54,200,000 | 49,806,000 | 49,286,000 | 42,002,000 | 42,540,000 | 37,375,000 | 42,174,000 | 35,655,000 | ||||||||||||||||||||
| total cost and operating expenses | 190,499,000 | 187,569,000 | 177,158,000 | 181,202,000 | 174,939,000 | 177,066,000 | 185,546,000 | 185,551,000 | 187,494,000 | 188,580,000 | 190,254,000 | 194,185,000 | 168,535,000 | 423,157,000 | 141,284,000 | 135,806,000 | 121,814,000 | 120,072,000 | 111,751,000 | 133,380,000 | 119,825,000 | ||||||||||||||||||||
| other income: | |||||||||||||||||||||||||||||||||||||||||
| interest expense | -8,129,000 | -7,775,000 | -7,616,000 | -6,864,000 | -5,895,000 | -3,406,000 | -3,808,000 | -2,500 | -6,000 | -2,000 | -4,000 | -14,000 | -23,000 | -32,000 | -43,000 | -47,000 | -59,000 | -72,000 | -94,500 | -109,000 | -129,000 | -140,000 | -161,000 | -171,000 | -179,000 | -185,000 | |||||||||||||||
| other income | 461,000 | -306,000 | 587,000 | -1,000 | 376,000 | -577,000 | -728,000 | -626,000 | 986,000 | 1,429,000 | 396,000 | 632,000 | -453,000 | -380,000 | -522,000 | -373,000 | -214,000 | 50,000 | -192,000 | -23,000 | -201,000 | -10,695,000 | 3,692,000 | 4,235,000 | 2,669,000 | 2,824,000 | 2,799,000 | 2,442,000 | 2,394,000 | 1,109,000 | 954,000 | 861,000 | 425,000 | 201,000 | 158,000 | 131,000 | 61,000 | 6,000 | 6,000 | -405,000 | -37,000 |
| equity investment gain | 50,039,000 | ||||||||||||||||||||||||||||||||||||||||
| debt extinguishment gain | 18,000 | 173,658,000 | |||||||||||||||||||||||||||||||||||||||
| total other income | 42,371,000 | -8,081,000 | -7,029,000 | -6,847,000 | 168,139,000 | -5,746,000 | -4,536,000 | -4,622,000 | -4,833,000 | -7,811,000 | -8,000,000 | 1,059,000 | -11,000 | 83,000 | 30,000 | 260,000 | 524,000 | 986,000 | 981,000 | 1,563,000 | 2,703,000 | 3,047,000 | 3,686,000 | 4,233,000 | 2,666,000 | 2,820,000 | 2,785,000 | 2,419,000 | 2,362,000 | 1,066,000 | 907,000 | 802,000 | 353,000 | 110,000 | 49,000 | 2,000 | -79,000 | -155,000 | -165,000 | -584,000 | -222,000 |
| income before income taxes | 1,285,000 | -49,284,000 | -56,003,000 | -49,892,000 | 89,316,000 | -110,855,000 | -133,516,000 | -132,603,000 | -129,040,000 | -157,610,000 | -132,277,000 | -156,579,000 | -105,815,000 | -316,053,000 | -117,066,000 | -108,251,000 | -84,980,000 | 634,348,000 | |||||||||||||||||||||||
| income tax expense | 789,000 | 672,000 | 273,000 | 102,000 | 180,000 | 61,000 | 197,000 | 190,000 | 520,000 | 9,436,000 | -886,000 | -3,130,000 | 184,000 | 2,633,000 | 175,000 | -193,000 | 688,000 | 370,000 | |||||||||||||||||||||||
| net income | 496,000 | -49,956,000 | -56,276,000 | -49,994,000 | 89,136,000 | -110,916,000 | -133,713,000 | -132,793,000 | -129,560,000 | -158,646,000 | -133,163,000 | -159,709,000 | -105,999,000 | -318,686,000 | -117,241,000 | -108,444,000 | -99,714,000 | -85,668,000 | 633,978,000 | -123,474,000 | -110,955,000 | -66,331,000 | -94,275,000 | -99,681,000 | -87,407,000 | -80,322,000 | -72,723,000 | -27,048,000 | -56,549,000 | -49,027,000 | -37,703,000 | -33,412,000 | -27,977,000 | -21,263,000 | -16,834,000 | -18,894,000 | -15,504,000 | -15,575,000 | -12,642,000 | -12,980,000 | -11,572,000 |
| yoy | -99.44% | -54.96% | -57.91% | -62.35% | -168.80% | -30.09% | 0.41% | -16.85% | 22.23% | -50.22% | 13.58% | 47.27% | 6.30% | 272.00% | -118.49% | -12.17% | -10.13% | 29.15% | -772.48% | 23.87% | 26.94% | -17.42% | 29.64% | 268.53% | 54.57% | 63.83% | 92.88% | -19.05% | 102.13% | 130.57% | 123.97% | 76.84% | 80.45% | 36.52% | 33.16% | 45.56% | 33.98% | ||||
| qoq | -100.99% | -11.23% | 12.57% | -156.09% | -180.36% | -17.05% | 0.69% | 2.50% | -18.33% | 19.14% | -16.62% | 50.67% | -66.74% | 171.82% | 8.11% | 8.76% | 16.40% | -113.51% | -613.45% | 11.28% | 67.27% | -29.64% | -5.42% | 14.04% | 8.82% | 10.45% | 168.87% | -52.17% | 15.34% | 30.03% | 12.84% | 19.43% | 31.58% | 26.31% | -10.90% | 21.87% | -0.46% | 23.20% | -2.60% | 12.17% | |
| net income margin % | 0.33% | -34.13% | -43.90% | -36.19% | 92.74% | -154.14% | -236.38% | -230.66% | -204.72% | -409.08% | -201.83% | -437.00% | -168.97% | -297.78% | -484.71% | -397.30% | -462.15% | -251.18% | 85.08% | -1479.97% | -1799.17% | ||||||||||||||||||||
| other comprehensive income: | |||||||||||||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale investments | 457,000 | ||||||||||||||||||||||||||||||||||||||||
| currency translation adjustments | -143,000 | 7,000 | -119,000 | -96,000 | 212,000 | -166,000 | 95,000 | 20,000 | 22,000 | -208,000 | 265,000 | 170,000 | 43,000 | -102,000 | 174,000 | -114,000 | 517,000 | -214,000 | -43,000 | 6,000 | -27,000 | ||||||||||||||||||||
| comprehensive income | 810,000 | -50,037,000 | 88,784,000 | -317,147,000 | -117,079,000 | -88,942,000 | 633,158,000 | ||||||||||||||||||||||||||||||||||
| net income per share | 0.01 | -0.8 | -0.89 | -0.8 | 1.45 | -1.82 | -2.2 | -2.19 | -2.15 | -2.65 | -2.23 | -2.68 | -1.79 | -5.43 | -2 | -1.86 | -1.72 | -1.64 | 11.49 | -2.28 | -2.11 | -1.33 | -1.93 | -2.04 | -1.98 | -1.82 | -1.66 | -0.62 | -1.29 | -1.25 | -0.96 | -0.86 | -0.84 | -0.75 | -0.62 | -0.7 | -0.57 | -0.43 | -0.47 | -0.81 | -8.23 |
| weighted-average number of common shares used in net income per share - basic | 64,096 | 62,854 | 61,580 | 58,647 | 55,169 | ||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share - diluted | 66,526 | 62,854 | 63,802 | 58,647 | 56,786 | ||||||||||||||||||||||||||||||||||||
| collaboration loss sharing | -45,000 | 1,771,000 | 1,234,000 | 1,296,000 | 1,872,000 | 1,665,000 | 2,145,000 | 3,265,000 | 4,532,000 | 3,269,000 | |||||||||||||||||||||||||||||||
| other comprehensive loss: | |||||||||||||||||||||||||||||||||||||||||
| unrealized gains on available-for-sale investments | 607,000 | 2,939,000 | 53,000 | -564,000 | 1,906,000 | 1,443,000 | 361,000 | 5,819,000 | |||||||||||||||||||||||||||||||||
| comprehensive loss | -52,436,000 | -53,456,000 | -111,728,000 | -132,175,000 | -132,412,000 | -123,719,000 | -102,391,000 | -133,741,000 | -161,847,000 | -113,976,000 | -109,182,000 | -99,597,000 | -124,525,000 | -108,490,000 | -69,503,000 | -94,565,000 | -98,829,000 | -87,152,000 | -80,165,000 | -72,679,000 | -26,838,000 | -56,872,000 | -24,809,750 | -37,614,000 | -33,612,000 | -28,091,000 | -12,801,250 | -16,862,000 | -18,870,000 | -15,473,000 | |||||||||||
| weighted-average number of common shares used in net income per share - basic and diluted | 63,381 | 60,688 | 60,516 | 60,126 | 59,758 | 59,617 | 59,312 | 58,406 | 58,023 | ||||||||||||||||||||||||||||||||
| collaboration and license revenue | 3,591,000 | 923,000 | 2,338,000 | 17,694,000 | 24,218,000 | 8,717,000 | 9,843,000 | ||||||||||||||||||||||||||||||||||
| license revenue - related party | 27,500,000 | ||||||||||||||||||||||||||||||||||||||||
| interest income | -3,996,000 | -5,819,000 | -9,240,000 | -8,396,000 | 427,000 | 442,000 | 463,000 | 552,000 | 633,000 | 738,000 | 936,000 | 1,173,000 | 1,586,000 | 2,904,000 | |||||||||||||||||||||||||||
| unrealized losses on available-for-sale investments | -2,792,750 | -843,000 | -2,308,000 | -8,020,000 | |||||||||||||||||||||||||||||||||||||
| collaboration revenue | 8,093,000 | 38,890,000 | 86,992,000 | 6,918,000 | 15,862,000 | 12,621,000 | 27,418,000 | 738,810,000 | 2,663,000 | 2,709,000 | 51,533,000 | 9,139,000 | 5,110,000 | 730,000 | 1,033,000 | 1,095,000 | 41,439,000 | 954,000 | 1,628,000 | 8,068,000 | 5,890,000 | 5,840,000 | 7,691,000 | 6,160,000 | 7,065,000 | 6,856,000 | 4,635,000 | 3,426,000 | 2,687,000 | 652,000 | |||||||||||
| unrealized gain (losses) on available-for-sale investments | -258,750 | -12,000 | -624,000 | -400,000 | 164,500 | -777,000 | -1,057,000 | 2,492,000 | |||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share — basic and diluted | 62,857 | 60,558 | 54,217 | 52,655 | 47,829 | 48,921 | 48,843 | 44,097 | 43,867 | 43,915 | |||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||||||
| general and administrative | 32,265,000 | 25,647,000 | 21,923,000 | 16,553,000 | 13,643,000 | 12,041,000 | 12,333,000 | 9,911,000 | 8,092,000 | 7,378,000 | 6,833,000 | 5,683,000 | 4,991,000 | 4,893,000 | 4,688,000 | 4,646,000 | 3,624,000 | 4,222,000 | 3,840,000 | 2,770,000 | |||||||||||||||||||||
| total operating expenses | 120,911,000 | 107,100,000 | 109,024,000 | 90,803,000 | 84,175,000 | 76,603,000 | 70,906,000 | 59,865,000 | 51,721,000 | 46,678,000 | 40,104,000 | 34,170,000 | 29,064,000 | 23,043,000 | 25,961,000 | 22,281,000 | 20,055,000 | 15,903,000 | 15,083,000 | 12,002,000 | |||||||||||||||||||||
| changes in foreign currency translation adjustments | -2,500 | -3,000 | 7,000 | -15,000 | |||||||||||||||||||||||||||||||||||||
| changes in unrealized gain (losses) related to available-for-sale investments | 207,000 | -287,000 | 845,000 | 270,000 | |||||||||||||||||||||||||||||||||||||
| unrealized gain on investments | -17,000 | 44,000 | 210,000 | -36,750 | 89,000 | -200,000 | -114,000 | 6,750 | -28,000 | 24,000 | 31,000 | ||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share applicable to common stockholders — basic and diluted | 43,856 | 43,700 | 37,793 | 39,130 | 38,775 | 33,190 | 27,492 | 27,251 | 27,170 | 27,088 | 18,236 | 26,835 | 17,093 | 1,681 | |||||||||||||||||||||||||||
| unrealized loss on investments | -323,000 | ||||||||||||||||||||||||||||||||||||||||
| reconciliation of net income applicable to common stockholders: | |||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock dividends | -883,000 | -2,270,000 | |||||||||||||||||||||||||||||||||||||||
| net income applicable to common stockholders | -21,263,000 | -16,834,000 | -18,894,000 | -15,504,000 | -15,575,000 | -12,642,000 | -13,863,000 | -13,842,000 |
We provide you with 20 years income statements for Blueprint Medicines stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Blueprint Medicines stock. Explore the full financial landscape of Blueprint Medicines stock with our expertly curated income statements.
The information provided in this report about Blueprint Medicines stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.